AtriCure Q3 2023 Adj EPS $(0.20) Beats $(0.31) Estimate, Sales $98.29M Beat $96.73M Estimate
Portfolio Pulse from totan@benzinga.com
AtriCure (NASDAQ:ATRC) reported Q3 2023 earnings with losses of $(0.20) per share, beating the analyst consensus estimate of $(0.31) by 35.48%. The company also reported quarterly sales of $98.29 million, surpassing the analyst consensus estimate of $96.73 million by 1.61%. Both figures represent an increase from the same period last year.
November 01, 2023 | 8:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AtriCure's Q3 2023 earnings beat analyst estimates, with losses less than expected and sales higher than predicted. This could positively impact the company's stock.
AtriCure's better-than-expected Q3 2023 earnings report, with lower losses and higher sales than predicted, could lead to increased investor confidence and a potential rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100